In 2006, cetuximab, a chimeric antibody (Ab) that targeted EGFR, was included in HNSCC regimens after a phase III trial and showed a survival benefit for cetuximab+RT compared with RT alone [5]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.